Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.
The internet is full of false claims. Columnist Sam Kirton shares why fact-checking is important, particularly for the rare disease world.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback